Printer Friendly

CEPHALON APPOINTS NEW SCIENCE ADVISORY BOARD MEMBER

 CEPHALON APPOINTS NEW SCIENCE ADVISORY BOARD MEMBER
 WEST CHESTER, Pa., Dec. 11 /PRNewswire/ -- Cephalon, Inc.


(NASDAQ: CEPH) announced today Dr. Philip S. Portoghese has joined its Science Advisory Board. Portoghese is currently a professor of medicinal chemistry and pharmacology at the University of Minnesota in Minneapolis.
 According to Dr. Frank Baldino, president and CEO of Cephalon, "Dr. Portoghese will enhance Cephalon's competitive position as a leading neuroscience/pharmaceutical company. His expertise in medicinal chemistry will directly impact all of the company's small molecule programs. Moreover, his knowledge of general pharmacology will embellish our drug development capabilities."
 Portoghese joined the University of Minnesota in 1961 and held increasingly important positions in the Department of Medicinal Chemistry and Pharmacology. Over the years, Portoghese has been a leader in the field and a recipient of a number of honors and awards. Most recently, he was presented the Edward E. Smissman-Bristol-Myers Squibb Award by the Division of Medicinal Chemistry, American Chemical Society and the Research Achievement Award in Medicinal Chemistry by the American Association of Pharmaceutical Scientists.
 Portoghese is on the advisory board of a number of publications and has been editor-in-chief of the Journal of Medicinal Chemistry since 1972. In addition, he has authored or co-authored 200 publications and over 140 abstracts.
 On the Science Advisory Board, Portoghese will join Dr. Stanley Cohen, professor, Department of Biology, Vanderbilt University Medical Center, Nobel prize in Medicine (1986); Dr. Stanley Appel, professor and chairman, Department of Neurology, Baylor College of Medicine; Dr. Gordon Guroff, associate director, National Institute of Child Health and Human Development, National Institute of Health; Dr. Robert Moore, director, Center for Neurosciences and professor of psychiatric and behavioral neuroscience, University of Pittsburgh; and Dr. Robert Roth, professor, Department of Pharmacology and Psychiatry, Yale Medical School.
 Cephalon, Inc. was founded in 1987 to discover, develop and commercialize novel therapeutic products for the treatment of stroke and neurodegenerative disorders.
 -0- 12/11/91
 /CONTACT: Nicole Vitullo of Cephalon, 215-344-0200/
 (CEPH) CO: Cephalon, Inc. ST: Pennsylvania IN: MTC SU: PER


JT -- NY005 -- 1297 12/11/91 08:00 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 11, 1991
Words:344
Previous Article:WAL-MART STORES SUPPORT COMMUNITIES; PERCENTAGE OF SALES DONATED TO CHRISTMAS CHARITIES
Next Article:EXECUTIVES SEE 'PARENT TRACKING' AS WAVE OF FUTURE Survey Shows High Sensitivity to Balance of Work and Family
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters